Phase 1 Long COVID Trial, Recruiting NCT07093580 Sponsor: Shionogi Condition: Long COVID
Back to Long Covid

Phase 1 Long COVID Trial, Recruiting

NCT07093580
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your Body Mass Index (BMI) — a measure of body weight relative to height — must be between 18.5 and 32.0 (confirm with trial site for exact measurement)

Who may not be able to join:

  • You have, or have had in the past, significant problems with your heart, lungs, liver, kidneys, stomach or digestive system, hormones, blood, nervous system, or eyes (such as high pressure in the eyes) that could affect how your body processes medicines or that could put you at risk during the study
  • You have a history of cancer, unless it was a certain type of skin cancer that was fully removed with no signs of spread for at least 3 years
  • You currently need to take any medication or follow any special treatment, such as a restricted diet or physical therapy
  • You have taken part in another clinical research study, or are currently in one, within the last 30 days (or longer, depending on the study drug involved)
  • You tested positive for hepatitis B, hepatitis C, or HIV at screening or within the 6 months before receiving the study treatment
  • You test positive for COVID-19 (SARS-CoV-2) when you check in for any study visit
  • You have a known allergy or sensitivity to any ingredient in the study drug or its placebo (dummy version)
  • You have used cannabis, tobacco, or any nicotine-containing products — including e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, or nicotine gum — within the 6 months before joining the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 800-849-9707

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Shionogi
Registry
ClinicalTrials.gov
Start date
29 July 2025
Est. completion
26 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs); Part 2: Number of Participants With TEAEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov